The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sorokina N.D.

Russian University of Medicine

Pertsov S.S.

Russian University of Medicine;
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies

Zherdeva A.S.

Municipal Clinical Hospital No. 15 named after O.M. Filatov

Selitsky G.V.

Russian University of Medicine

Factors and features of the development of epilepsy in patients with multiple sclerosis

Authors:

Sorokina N.D., Pertsov S.S., Zherdeva A.S., Selitsky G.V.

More about the authors

Read: 590 times


To cite this article:

Sorokina ND, Pertsov SS, Zherdeva AS, Selitsky GV. Factors and features of the development of epilepsy in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;124(10):18‑27. (In Russ.)
https://doi.org/10.17116/jnevro202512510118

Recommended articles:
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
FA2H gene-associated spastic para­plegia (SPG35) — fami­lial case with late onset. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):137-144

References:

  1. Absinta M, Lassmann H, Trapp BD. Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol. 2020;33(3):277-285.  https://doi.org/10.1097/WCO.0000000000000818
  2. Gusev EI, Boyko AN. Rasseyannyj skleroz. Nauchno-prakticheskoe rukovodstvo v dvuh tomah. M.: ROOI «Human Health»; 2020. (In Russ.).
  3. Yang J, Hamade M, Wu Q, et al. Current and Future Biomarkers in Multiple Sclerosis. Int J Mol Sci. 2022;23(11):5877. https://doi.org/10.3390/ijms23115877
  4. Popova EV, Boiko AN, Khachanova NV, et al. Epstein-Barr virus in the pathogenesis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(2-2):29-34. (In Russ.).
  5. Antal DC, Schreiner TG, Crihan TE, et al. Seizures and multiple sclerosis-more than an epidemiological association. Exp Ther Med. 2022;24:689. 
  6. Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis. Mult Scler J. 2015;21(3):263-281.  https://doi.org/10.1177/1352458514564491
  7. Sponsler JL, Kendrick-Adey AC. Seizures as a manifestation of multiple sclerosis. Epileptic Disord. 2011;13 (4):401-410. 
  8. Neus RF, Podewils F, Wang ZI, et al. Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy. J Neurol. 2021;268:1721-1727. https://doi.org/10.1007/s00415-020-10346-z
  9. Belova YuA, Yakushina TI, Rudakova IG, et al. Epileptic seizures in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(8-2):47-48. (In Russ.).
  10. Mahamud Z, Burman J, Zelano J. Temporal trends of epilepsy in multiple sclerosis. Acta Neurol Scand. 2022;146:492-498.  https://doi.org/10.1111/ane.13671
  11. Mirmosayyeb O, V. Shaygannejad V, Nehzat N, et al. Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis. Int J Prev Med. 2021;24:12:14.  https://doi.org/10.4103/ijpvm.IJPVM_75_20
  12. Boyko AN, Dolgushin MB, Karalkina MA. New neuroimaging methods in assessing the activity of neuroinflammation in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7-2):8-14. (In Russ.). https://doi.org/10.17116/jnevro20231230728
  13. Grothe M, Ellenberger D, Rommer PS, et al. Epileptic seizures at multiple sclerosis onset and their role in disease progression. Ther Adv Neurol Disord. 2023;16:1-8.  https://doi.org/10.1177/17562864231192826
  14. Nicholas R, Magliozzi R, Campbell G, et al. Temporal lobe cortical pathology and inhibitory GABA interneuron cell loss are associated with seizures in multiple sclerosis. Mult Scler J. 2016;22(1):25-35.  https://doi.org/10.1177/1352458515579445
  15. Karlov VA. Epilepsiya u detej i vzroslyh zhenshchin i muzhchin. Rukovodstvo dlya vrachej. M.: 2-e izdanie Izdatel’skij Dom «Binom»; 2019. (In Russ.).
  16. Kavcic A, Hofmann WE. Unprovoked seizures in multiple sclerosis: Why are they rare? Brain Behav. 2017;7(7):e00726. https://doi.org/10.1002/brb3.726
  17. Catenoix H, Marignier R, Ritleng C, et al. Multiple sclerosis and epileptic seizures. Mult Scler. 2011;17:96-102.  https://doi.org/10.1177/1352458510382246
  18. Belova YuA, Yakushina TI, Rudakova IG, et al. Epilepsy in patients with multiple sclerosis. Features of diagnosis and therapy. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2014;1:41-46. (In Russ.). https://doi.org/10.14412/2074-2711-2015-1S-41-46
  19. Muzhikina NV, Koroleva NYu, Kataeva GV, et al. Structural epilepsy in multiple sclerosis. Rossijskij nevrologicheskij zhurnal. 2023;28(1):62-66. (In Russ.). https://doi.org/10.30629/2658-7947-2023-28-1-62-66
  20. Steriade C, Titulaer MJ, Vezzani A, et al. The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain. 2021;144 (2):372-390.  https://doi.org/10.1093/brain/awaa362
  21. Tran S, Mathon B, Morcos-Sauvain E, et al. Neuropathology of Epilepsy. Ann Pathol. 2020;40(6):447-460.  https://doi.org/10.1016/j.annpat.2020.08.001
  22. Wei F, Yan L, Su T, et al. Ion Channel Genes and Epilepsy: Functional Alteration, Pathogenic Potential, and Mechanism of Epilepsy. Neurosci Bull. 2017;33(4). 455-477.  https://doi.org/10.1007/s12264-017-0134-1
  23. Vlaicu MB. Epilepsy in multiple sclerosis as a network disease. Mult Scler Rel Disord. 2019;36:101390. https://doi.org/10.1016/j.msard.2019.101390.
  24. Fleischer V, Radetz A, Ciolac D, et al. Graph theoretical framework of brain networks in multiple sclerosis. Neuroscience. 2019;403(56):35-53  https://doi.org/10.1016/j.neuroscience.2017.10.033
  25. Groppa S, Gonzalez-Escamilla G, Eshaghi A, et al. Linking immune-mediated damage to neurodegeneration in multiple sclerosis: could networkbased MRI help? Brain Com. 2021;3(4):fcab237. https://doi.org/10.1093/braincomms/fcab237
  26. Ciolac D, Gonzalez-Escamilla G, Winter Y, et al. Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis. Eur J Neurol. 2022;29 (8):2309-2320. https://doi.org/10.1111/ene.15405
  27. Melnikov MV, Sviridova AA, Rogovsky VS, et al. The role of macrophages in the development of neuroinflammation in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(5):51-56. (In Russ.). https://doi.org/10.17116/jnevro202212205151
  28. Khaboushan AS, Yazdanpanah N, Rezaei N. Neuroinflammation and Proinflammatory Cytokines in Epileptogenesis. Mol Neurobiol. 2022;59(3):1724-1743. https://doi.org/10.1007/s12035-022-02725-6
  29. Calabrese M, De Stefano N, Atzori M, et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol. 2008;255(4):581-586. 
  30. Eliseeva DD, Zakharova MN. Mechanisms of Neurodegeneration in Multiple Sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7-2):5-13. (In Russ.). https://doi.org/10.17116/jnevro20221220725
  31. Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist. 2005;11(1):37-49.  https://doi.org/10.1177/1073858404269012
  32. Hu X, Wang JY, Gu R, et al. The relationship between the occurrence of intractable epilepsy with glial cells and myelin sheath — an experimental study. Eur Rev Med Pharmacol Sci. 2016;20(21):4516-4524.
  33. Kim SH, Choi J. Pathological classification of focal cortical dysplasia (FCD): personal comments for well understanding FCD classification. J Korean Neurosurg Soc. 2019;62(3):288-295.  https://doi.org/10.3340/jkns.2019.0025
  34. Bronisz E, Kurkowska-Jastrzębska I. Matrix Metalloproteinase-9 in Epilepsy: The Role of Neuroinflammation in Seizure Development. Mediators Inflamm. 2016:2016:7369020. https://doi.org/10.1155/2016/7369020
  35. Nobili P, Shen W, Milicevic K. Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis. Front Pharmacol. 2022;2(13):900337. https://doi.org/10.3389/fphar.2022.900337
  36. Suhail H, Nematullah V, Rashid F, et al. An early glycolysis burst in microglia regulates mitochondrial dysfunction in oligodendrocytes under neuroinflammation. iScience. 2023;26(10):107921. https://doi.org/10.1016/j.isci.2023.107921
  37. Louapre C, Lubetzki C. Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes. Mult Scler J. 2015;21:1626-1628. https://doi.org/10.1177/1352458515587598
  38. Cai Y, Yang Z. Ferroptosis and Its Role in Epilepsy. Front Cell Neurosci. 2021;15 (15):696889. https://doi.org/10.3389/fncel.2021.696889
  39. Cheng Y, Song Y, Chen H, et al. Ferroptosis Mediated by Lipid Reactive Oxygen Species: A Possible Causal Link of Neuroinflammation to Neurological Disorders. Oxid Med Cell Longevity. 2021:5005136. https://doi.org/10.1155/2021/5005136
  40. Ruetten PP, Gillard JH, Graves MJ. Introduction to Quantitative Susceptibility Mapping and Susceptibility Weighted Imaging. Br J Radiol. 2019;92(1101):20181016. https://doi.org/10.1259/bjr.20181016
  41. Filippi M, Brück W, Chard D, et al. Attendees of the Correlation between Pathological and MRI findings in MS workshop. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2019;18(2):198-210.  https://doi.org/10.1016/S1474-4422(18)30451-4
  42. Clarke MA, Lakhani DA, Sijin W, et al. Perilesional neurodegenerative injury in multiple sclerosis: Relation to focal lesions and impact on disability. Mult Scler Relat Disord. 2021;49:102738. https://doi.org/10.1016/j.msard.2021.102738
  43. Chen A, Wen S, Lakhani DA, et al. Assessing brain injury topographically using MR neurite orientation dispersion and density imaging in multiple sclerosis. J Neuroimaging. 2021;31(5):1003-1013. https://doi.org/10.1111/jon.12876
  44. Calabrese M, Castellaro M, Bertoldo A, et al. Epilepsy in multiple sclerosis: The role of temporal lobe damage. Mult Scler J. 2017;23(3):473-482.  https://doi.org/10.1177/1352458516651502
  45. Spano B, Giulietti G, Pisani V, et al. Disruption of neurite morphology parallels MS progression. Neurol Neuroimmunol Neuroinflam. 2018;5(6):e502. https://doi.org/10.1212/NXI.0000000000000502
  46. Allen AN., Seminog OO, Goldacre MJ. Association between multiple sclerosis and epilepsy: large population-based recordlinkage studies. BMC Neurol. 2013;13:189.  https://doi.org/10.1186/1471-2377-13-189
  47. Grothe M, Ellenberger D, Podewils F, et al. Epilepsy as a predictor of disease progression in multiple sclerosis. Mult Scler. 2022;28: 942-949. 
  48. Vezzani A, Friedman A, Dingledine RJ. The role of inflammation in epileptogenesis. Neuropharmacology. 2013;69:16-24.  https://doi.org/10.1016/j.neuropharm.2012.04.004
  49. Boĭko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2-2):92-106. (In Russ.). https://doi.org/10.17116/jnevro20171172292-106
  50. Schuele SU., Kellinghaus C, Shook SJ et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology. 2005;64(6):1086-1087. https://doi.org/10.1212/01.WNL.0000154639.35941.21
  51. Stefanovic S, Jankovic SM, Novakovic M, et al. Pharmacodynamics and common drug-drug interactions of the third-generation antiepileptic drugs. Expert Opin Drug Metab Toxicol. 2018;14(2):153-159.  https://doi.org/10.1080/17425255.2018.1421172
  52. Perucca E. Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disord. 2019;21(4):319-329.  https://doi.org/10.1684/epd.2019.1083
  53. Selton M, Mathey G, Soudant M, et al. Prognostic impact of epileptic seizures in multiple sclerosis varies according to time of occurrence and etiology. Eur J Neurol. 2022;29:3537-3546. https://doi.org/10.1111/ene.15551
  54. Martinez-Juarez IE, Lopez-Meza E, Gonzalez-Aragon MC, et al. Epilepsy and multiple sclerosis: Increased risk among progressive forms. Epilepsy Res. 2009;84 (2-3):250-253. 
  55. Sponsler JL, Kendrick-Adey AC. Seizures as a manifestation of multiple sclerosis. Epileptic Disord. 2011;13(4):401-410. 
  56. Zavalishin IA, Eliseeva DD. Treatment of multiple sclerosis. Doktor.ru. 2009;4:25-29. (In Russ.).
  57. Striano P, Orefice G, Morra BV, et al. Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurol Sci. 2003;24:322-328.  https://doi.org/10.1007/s10072-003-0183-2
  58. Spatt J, Chaix R, Mamoli B. Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol. 2001;248(1):2-9. 
  59. Lebrun C, Bensa C, Debouverie M. et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry. 2008;79(2):195-8.  https://doi.org/10.1136/jnnp.2006.108274
  60. Khabirov FA, Khaibullin TI, Granatov EV, et al. Epilepsy in multiple sclerosis. Prakticheskaya Medicina. 2015;15 (2). (In Russ.).
  61. Kelley BJ, Rodriguez M. Seizures in Patients with Multiple Sclerosis: Epidemiology, Pathophysiology and Management. CNS Drugs. 2009;23(10):805-815.  https://doi.org/10.2165/11310900-000000000-00000
  62. Newman P, Saunders M. A unique case of musicogenic epilepsy. Arch Neurol. 1980;37(4):244-245. 
  63. Villamar MF, Sarkis RA, et al. Severity of epilepsy and response to antiseizure medications in individuals with multiple sclerosis: analysis of a real-world dataset. Neurol Clin Pract. 2022;12(4):e49-e57.  https://doi.org/10.1212/CPJ.0000000000001178
  64. Eriksson M, Ben-Menachem E, Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler. 2002;8(6):495-499.  https://doi.org/10.1191/1352458502ms812oa
  65. Arslan G, Demir B. Cognitive impairment in epilepsy patients and its correlations. Appl Neuropsychol Adult. 2024;31(6):1405-1410. https://doi.org/10.1080/23279095.2022.2133606
  66. Damulin IV. The main mechanisms of neuroplasticity and their clinical significance. S.S. Korsakov Journal of Neurology and Psychiatry. 2009;109 (4):4-8. 
  67. Gusev EI., Kamchatnov PR. Plasticity of the nervous system. S.S. Korsakov Journal of Neurology and Psychiatry. 2004;104(3):73-79. (In Russ.).
  68. Peresedova AV, Zavalishin IA. Compensatory mechanisms in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;2:17-22. (In Russ.)
  69. Kesserling G, Comi G, Thompson AJ. Multiple sclerosis: recovery of function and neurorehabilitation. Cambridge: Cambridge University Press; 2010.
  70. Karlov VA. The doctrine of the epileptic system. The merit of the national scientific school. Epilepsiya i Paroksizmal’nye Sostoyaniya. 2017;9(4):79-85. (In Russ.). https://doi.org/10.17749/2077-8333.2017.9.4.076-085
  71. Lenzi DA. Conte A, Mainero C, et al. Effect of corpus callosum damage on ipsilateral motor activation in patients with multiple sclerosis: a functional and anatomical study. Human Brain Mapping. 2017;9(4):79-85.  https://doi.org/10.1002/hbm.20305
  72. Hawellek DJ, Hipp JF, Lewis CM, et al. Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis. Proc Nat Acad Sci USA. 2011;108 (47):19066-19071. https://doi.org/10.1073/pnas.1110024108
  73. Newcombe J, Uddin A, Dove R, et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol. 2008;18(1):52-61.  https://doi.org/10.1111/j.1750-3639.2007.00101.x
  74. Bassi MS, Iezzi E, Centonze D. Multiple sclerosis: Inflammation, autoimmunity and plasticity. Handb Clin Neurol. 2022;184:457-470.  https://doi.org/10.1016/B978-0-12-819410-2.00024-2
  75. Karlov V.A. Epilepsiya u detej i vzroslyh zhenshchin i muzhchin. Rukovodstvo dlya vrachej. Moskva: Binom; 2023. (In Russ.).
  76. Yu C, Deng X, Xu D. Microglia in epilepsy. Neurobiol Dis. 2023;185:106249. https://doi.org/10.1016/j.nbd.2023.106249
  77. Scharfman HE. Epilepsy as an Example of Neural Plasticity. Neuroscientist. 2002;8(2):154-173.  https://doi.org/10.1177/107385840200800211
  78. Sutula TP. Mechanisms of epilepsy progression: current theories and perspectives from neuroplasticity in adulthood and development. Epilepsy Res. 2004;60(2-3):161-71.  https://doi.org/10.1016/j.eplepsyres.2004.07.001
  79. Stampanoni BM, Iezzi E, Centonze D, et al. Handb Multiple sclerosis: Inflammation, autoimmunity and plasticity. Clin Neurol. 2022;184:457-470.  https://doi.org/10.1016/B978-0-12-819410-2.00024-2

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.